Business Wire

Industrial Transformation Takes Center Stage at Cognite’s Global “Ignite Talks” October 27-29

6.10.2020 14:00:00 EEST | Business Wire | Press release

Share

Cognite, a leader in industrial innovation, will host its third annual global conference “Ignite Talks: Industrial Intelligence Augmented: Reimagining How Minds and Machines Work Together” from Oct. 27-29, 2020. The free virtual event will feature global leaders and innovators who are driving industries and supply chains toward a more innovative, data-driven, sustainable future.

“The world is at a technological, economic, and environmental crossroads like never before, and we are looking forward to discussing pressing issues among some of the industry’s best,” said John Markus Lervik, Cognite CEO.

The full agenda for this free online conference can be found here and at www.cogniteignite.com.

Day-by-day overviews and panel highlights are listed below:

October 27: Igniting Industrial Transformation: Europe & Norway’s Leading Role

Opening day spotlights how leaders in Europe are melding minds and machines, and inspiring a transformation of heavy-asset industries and supply chains. Panel highlights:

  • What's Next for the Global Energy Transition: The energy transition is here. Can the oil and gas industry adapt, or is it the end of the industry as we know it?
    • Speakers: Bernard Looney, CEO, BP; Ahmad A. Al-Sa’adi, SVP of Technical Services, Saudi Aramco; Øyvind Eriksen, President and CEO, Aker ASA
  • Reinventing Industrial Supply Chains Post-COVID Through Digital Innovation: 2020 has presented the world with a chance to rethink global supply chains. How do we seize the opportunity?
    • Speakers: Sameer Kalra, President Marine Division, Alfa Laval; Victoria Van Camp, CTO, SKF

October 28: America’s Industrial Transformation

The technology prowess of the United States and raw innovative capacity is unmatched, and its heavy-asset industries are taking steps to leverage technology at scale in order to jump-start digital transformations. What will it take to succeed, what role does technology play? Panel highlights:

  • America’s Energy Transition - in partnership with Axios: A live, virtual event, featuring in-depth 1:1 discussions with industry leaders and policymakers on the development of renewable energy in the US, how the coronavirus pandemic has affected energy patterns, and what’s next for the US oil & gas industry. This panel will be hosted by Axios energy and climate change reporter Amy Harder.
  • Industry Under Siege: A New Era of Industrial Cybersecurity: Sophisticated cybercriminals are setting their sights on industry. How can industrial companies digitalize operations while minimizing risk?
    • Speakers: Ron Brash, Director of Cyber Security Insights, Verve Industrial Protection; Tomomi Aoyama, Head of Business Development UK, Nihon Cyber Defence
  • Navigating the Digital Transition to Renewable Energy
    • Speakers: Ashtad Engineer, VP Digital & Transformation, Adani; Astrid Skarheim Onsum, CEO, Aker Offshore Wind

October 29: Driving a Global Transformation from the Bottom Up

The domains and technologies behind the scenes are the real drivers of industrial transformation. The final day gives an insider's view into technology adoption, empowering users with data and domain-specific insights into subsurface and exploration, detection and warning, ocean data, sustainability, and more. Panel highlights:

  • Operationalize and Scale Models and Applications with Trusted Industrial Data: Data issues are still holding back digitalization initiatives. Experts from Forrester and Wintershall Dea explain how to break down barriers and generate meaningful ROI.
    • Speakers: Patrick von Pattay, VP of Intelligent Operations, Wintershall DEA; Paul Miller, Principal Analyst, Forrester
  • Cleaning Up Our Act: Data-Driven Sustainability in Upstream Oil & Gas: Reducing emissions has become the responsibility of every oil and gas company. BP explains how digitalization is powering its sustainable transformation.
    • Speaker: Rob Kelly, Head of Upstream Digital, BP
  • Waves of Change: Using Data to Advance Ocean Sustainability: The oceans are under siege. In this session, leading ocean experts explain how industry can use data to turn the tide.
    • Speakers: Craig McLean, Assistant Administrator of Oceanic and Atmospheric Research, National Oceanic and Atmospheric Administration; Bjørn Tore Markussen, CEO at Center for the 4th Industrial Revolution for the Ocean

About Cognite

Cognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedata

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michelle Holford
Global PR Lead - Cognite
+15127443420 (US)
+4748290454 (Norway)
michelle.holford@cognite.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye